Welcome to Heart Health Care, LLC

29th Nurse Practitioner Symposium
July 15-18, 2004
Keystone, Colorado

Update on Dyslipidemia Rx LE

Industry Sponsored Symposium
July 16th

Recognize how to select the appropriate lipid-lowering agent (LLA) or agents for lipid abnormalities; steps for using combination therapy to avoid adverse outcomes; and the use of LLA in the elderly, women and children. Case studies will be used throughout the program. Audience participation is encouraged; bring your difficult lipid profiles.

Frances Stier, MSN,ANP,ACNP;
Nurse Practitioner,
Northern Arizona Heart Center; Show Low AZ

Sponsored by an unrestricted educational grant from AstraZeneca.

Materials from Fran's presentation:

• Objectives: At the end of the presentation, the speaker hopes that the participants will be able to:
  
  1. Apply the ATP III guidelines to specific patient profiles.
  2. Select the appropriate lipid-lowering agent (LLA) for the lipid abnormality.
  3. Describe the indications and monitoring for combination therapy.
  4. Describe the benefits of statin therapy beyond lowering of cholesterol.
  5. Describe lipid-lowering in special populations.
  
   
• Outline:
  
  1. Summarize key points of the ATP III guidelines
  2. Lipoproteins and subfractions.
  3. Medical conditions that indicate CAD equivalent.
  4. Calculating 10-year risk for CAD.
  5. Lipid-lowering agents: categories, indications, dose, and effect on specific lipoproteins and triglycerides.
  6. Steps to follow in using combination therapy.
  7. Monitoring for ADRs
  8. Beyond lipid-lowering: stroke prevention and plaque stabilization.
  9. When to use LLA in the elderly, women and children
  
   
• Bibliography:
  
  1. Bussoletti A. Framingham Point Score: A useful tool in assessing CHD risk. The Journal for Nurse Practitioners. 2003; 7(9): 17-24.
  2. Executive Summary of the Third Report of the National Cholesterol Educational Program (NCEP) Expect Panel on Detection, Evaluating and Treatment of High Blood Cholesterol in Adults (ATP III). JAMA. 2001;285(19):2486-2497.
  3. Foody JM, Krumlotz HM. Are statins indicated for the primary prevention of CAD in octogenarians? Antagonist viewpoint. The Am.Joun.Geriatric Cardiology. 2003;12(6):357-360.
  4. Jones PH, Davidson MH, Stein EA, et.al. Comparison of the efficacy and safety of Rosuvastatin versus Atorvastatin, simvastatin, and Pravastatin across doses (Stellar Trial). The American Joun. Of Cardiology. 2003;92:152-160.
  5. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin of 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360(9326):7-22.
  6. Pasternak RC, Smith SC,jr., Baiirey-Merz CN, Grundy SM, Cleeman JR, Lenfant C. ACC/AHA/NHLBI Clinical advisory on the use and safety of statins. Circulation. 2002;106(8):1024-1028.
  7. Stone NJ. an Are statins indicated for the primary prevention of CAD in octogenarians? Protagonist viewpoint. The Am.Joun.Geriatric Cardiology. 2003;12(6):351-354.
  
   
• Internet Resources:
  
  1. www.Nhlbi.nih.gov/guidelines/cholesterol/atpiii.htm
  2. www.heartcenteronline.com The Cholesterol Center. Palm OS applications. 10-year Risk Calculator
  3. www.lipidhealth.org
  4. www.americanheart.org
  
   
• Seminar Handout* (183Kb)
   
• Slide presentation* (2.3Mb - 11 min @ 28.8Kbps)

* To view these materials in PDF format, you will need the FREE Adobe Acrobat Reader, available here: